COMPANY PROFILE

Welcome To The Revolution

Our mission is to develop and commercialize, revolutionary micro-robotic medical technologies that can change the future of medicine. To that end we’ve introduced LIBERTY; the first, fully-disposable, non-capital intensive, truly portable, remote-site-controlled, robotic system for endoluminal surgical procedures.

Liberation from Capital Equipment

Liberation from Radiation Exposure

Liberation from Surgical Strain

Liberation from Multiple Consumables

… Leading the Revolution in Democratizing Cath-Lab Procedures

In addition to LIBERTY™, the Microbot Medical team is currently researching and developing the Self-Cleaning Shunt, or SCS™, for the treatment of hydrocephalus and normal pressure hydrocephalus.

Our team remains committed to utilizing our numerous patented technologies to improve the quality of life for millions of patients globally by advancing micro-robotic luminal technologies to perform multiple surgical procedures within the human body, while offering physicians and their patients less invasive and more precise medical solutions.

MANAGEMENT

Harel Gadot

PRESIDENTCHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS

Mr. Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACTRobotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, Mr. Gadot was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, Mr. Gadot served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. Mr. Gadot is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).

David Ben Naim

CHIEF FINANCIAL OFFICER

David Ben Naim is a CPA licensed in the State of Israel. During the past five years, Mr. Ben Naim has held the following positions: (i) from 2014 to the present, he has operated DBNFinancial, providing clients with full outsourcing financial and accounting services; (ii) from 2012 – 2014, he served as CFO of Insuline Medical Ltd, a public company organized under the laws of the State of Israel listed on the Tel-Aviv Stock Exchange (TASEINSL) focused on improving the performance of current insulin treatment methods. As CFO, Mr. Ben Naim reported to its CEO and worked closely with the Board and its various committees, planning and implementing the transition from the development stage into a TASE listed company and participating in the structure and raise of equity and debt capital, among other responsibilities; and (iii) from 2008 – 2011, Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, public company traded on the OTCQB (CRWTF), with responsibilities for planning and implementation of corporate financial strategy, reporting to the CEO and working closely with the Board and its various committees.

simon_hi_res

Simon Sharon

CHIEF TECHNOLOGY OFFICER

Mr. Sharon is a seasoned medical device executive with over 30 years of industry experience. Prior to rejoining Microbot, Simon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator with partners such as Boston Scientific Corporation and Intellectual Ventures. He was also the Chairman of the Scientific Board at XACT Robotics, a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Medical Ltd. before it became a publicly traded company. Prior to joining Microbot in 2013, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation–Anorad Israel Ltd, a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Simon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.

Eran Cohen

DIRECTOR OF BUSINESS DEVELOPMENT

Eran is an experienced executive and entrepreneur in the Life Sciences arena that co-founded and managed incubator-sponsored start-up companies in Israel. Prior to joining Microbot, Eran held senior Marketing & Business Development positions in Estar Medical (technologies and systems for the Regenerative Medicine arena), Beleaf Herbal (herbal supplements for the treatment of obesity, erectile dysfunction, diabetes and a range of skin and hair conditions) and Accellta Ltd (transformational technology for mass production of human embryonic and induced pluripotent stem cells, progenitors and differentiated cells for clinical and industrial applications). Eran serves as a business associate of Sama Brasil Comércio Internacional Ltda., a business development and trade company located in Brazil. Eran holds a BSc from the Hebrew University in Jerusalem and MBA from the Technion, Haifa.

Eyal-Headshot2018

Eyal Morag, MD

CHIEF MEDICAL OFFICER

Dr. Eyal Morag will lead the development and execution of the clinical strategy of the Company’s technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline. Dr. Morag has been a member of the Company’s Scientific Advisory Board since November 2017.

Concurrently, Dr. Morag also serves as Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel. Recently he served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio. He was a member of University Radiology Group (one of the largest private Radiology groups in the U.S.) where he headed the International Investment efforts for the Ventures division.

Dr. Morag has extensive international experience developing and establishing radiology-related businesses. During his fellowship, Dr. Morag co-founded InTek Technology, a medical device startup company. Later he founded Global Versa Radiology (GVR), an Israeli and U.S. based Teleradiology Company that has expanded reach to provide Interventional Radiology services to U.S. hospitals. Dr. Morag has served as GVR’s Chief Medical Officer and Vice-President.

Dr. Morag is certified by the American Board of Radiology and received his training at top medical institutions including:    Boston University School of Medicine, MD;   Brockton Hospital, an affiliate of Boston Medical Center & Boston University School of Medicine, Internship;   Beth Israel Deaconess Medical Center & Harvard Medical School, Radiology Residency;   Beth Israel Deaconess Medical Center & Harvard Medical School, Fellowship in Cardiovascular & Interventional Radiology.

Noa-Ofer-profile

Noa Ofer, PhD

INTELLECTUAL PROPERTY MANAGER

Dr. Noa Ofer oversees the development and expansion of Microbot Medical’s patent portfolio and innovation processes, directing all intellectual property aspects of the company. Dr. Ofer has vast experience in intellectual property counseling for a wide range of company stages, from start-up initial stage companies to mature corporations, specializing in the medical device industry.

Prior to joining Microbot Medical, Dr. Ofer provided patent drafting and prosecuting services with some of the top Intellectual Property firms in the country, including the Medical Device Department of Ehrlich & Fenster IP firm. Dr. Ofer then proceeded to counsel in-house for the largest dental implants company in the country, MIS Implants Technologies LTD, where she worked closely with the legal and patent department of the US based top tier dental company, Dentsply Sirona. Throughout the years, Dr. Ofer has advised and educated a multitude of start-up groups, including through participation in a variety of hackathon events.

Dr. Ofer holds a Bachelor of Arts in Biology (BA), a Master in Medical Sciences (MSc) and a PhD in Nanotechnology, all from the Technion – Israel Institute of Technology. She was licensed as an Israeli patent attorney in 2016.

BOARD OF DIRECTORS

Harel Gadot

PRESIDENTCHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS

Mr. Gadot is a co-founder of Microbot Medical and has been serving as the CEO since its inception and the Chairman of the Board since 2013. He is also the Chairman of XACTRobotics Ltd., another promising medical robotics company, specializing in the field of needle steering for medical procedures such as biopsies. Until 2013, Mr. Gadot was a board member at ConTIPI Ltd. Which was acquired in 2012 by Kimberly Clark. Prior to founding Microbot Medical, Mr. Gadot served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, he was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc., Paris, France), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, both companies enjoyed continuous growth in revenues and new product launches. Prior to this, Harel held several management positions in marketing and sales at Johnson & Johnson Medical Israel. Mr. Gadot is a guest speaker for management and innovation courses at leading universities in the United States and Israel, and holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).

Yossi Bornstein

DIRECTOR AND CO-FOUNDER

Mr. Bornstein is a co-founder of Microbot Medical and has been a member of the Board of Directors since the inception of the company. Mr. Bornstein is the owner and President of Shizim Ltd., a life science holding group in Israel. Mr. Bornstein was the General Manager at Bristol-Myers Squibb (Israel) until 1992 when he joined the private sector. He is the founder of a number of privately held life-science companies including Pharmateam Ltd., which was sold in 2000. Mr. Bornstein was the Biotechnology Committee Chairman of USISTC (Unites States-Israel Science & Technology Commission) as well as a consultant for USISTF (Unites States-Israel Science & Technology Foundation). He is also the founder of ILSI-Israel Life Science Industry Organization and ITTN-Israel Tech Transfer Organization.

Martin J. Madden

DIRECTOR

Mr. Madden’s diversified and extensive R&D experience in the development of medical devices includes hundreds of projects in multiple medical spaces, many of which reached successful commercialization stage. Mr. Madden recently retired from Johnson & Johnson after a 30 year career. He first joined Johnson & Johnson in 1986 and held a number of roles of increasing importance, including Vice President Research & Development for Orthopedics, Global Surgery and Interventional Vascular Divisions. Mr. Madden holds an MBA from Columbia University, a Master of Science in Mechanical Engineering from Carnegie-Mellon University and Bachelor of Science in Mechanical Engineering from the University of Dayton.

Scott Burell

DIRECTOR

Scott R. Burell. Since August 2018, Mr. Burell is the Chief Financial Officer of Aivita Biomedical, Inc., an Irvine California-based immuno-oncology company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. From November 2006, Mr. Burell served as Chief Financial Officer, Secretary and Treasurer of CombiMatrix Corporation (NASDAQCBMX), a publicly traded diagnostics laboratory, until it was acquired by Invitae Corporation (NYSENVTA) in November 2017. Prior to this, Mr. Burell had served as CombiMatrix’s Vice President of Finance and Controller since February 2001. From May 1999 to February 2001, Mr. Burell was the Controller for Network Commerce, Inc., (NASDAQSPNW), which was a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent nine years with Arthur Andersen’s Audit and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions. Mr. Burell is also a member of the Board of Directors of CollPlant Holdings Ltd., (NASDAQCLGN), an Israeli-based regenerative medicine company, and AgEagle Aerial Systems, Inc. (NYSEUAVS), a U.S.-based agricultural drone company. Mr. Burell obtained his Washington state CPA license in 1992 (currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.

Aileen Stockburger

DIRECTOR

Aileen Stockburger is a highly accomplished strategic planning and corporate transaction executive. She has managed and closed sizable worldwide mergers and acquisitions, licensing agreements, and divestitures, with cumulative purchase prices in excess of $70 Billion.

Ms. Stockburger had a distinguished career at Johnson & Johnson, where she held numerous business development and finance roles and served in various business areas. Aileen also served on several internal boards at Johnson & Johnson, including: J&J Worldwide Orthopaedics Group, J&J Comprehensive Care Group, Johnson’s Baby Care Global Management Board, and J&J Development Corp.

Most recently, Aileen was Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson. Prior to DePuy Synthes, Ms. Stockburger coordinated and led the Business Development efforts for the Medical Devices & Diagnostics companies of Johnson & Johnson. She also spent 10 years as the Vice President of Worldwide Mergers and Acquisitions for the Johnson & Johnson Consumer Group.

Before joining Johnson & Johnson, Aileen Stockburger spent several years at PriceWaterhouse Coopers, and earned her CPA certification. She received her MBA and BS from The Wharton School, University of Pennsylvania.

P. (Laxmin) Laximarain

DIRECTOR

Mr. Laxminarain is a successful medical device executive with over 30 years’ experience and proven track record, most recently served as Worldwide President of Codman Neurosurgery (a Johnson & Johnson company), which was acquired by Integra LifeSciences Holdings Corporation in October 2017 for approximately $1.045 billion. Mr. Laxminarain first joined Johnson & Johnson in 1986 where he held roles of increasing responsibility, including President of Codman Neurosurgery from 2006 to 2017. In addition, Mr. Laxminarain held senior medical device positions in India, Singapore and South Korea. Prior to Johnson & Johnson, he was a management consultant with AF Ferguson & Co., an audit and management consultancy business in India where he worked on strategy as well as execution related projects in a variety of industries. Mr. Laxminarain received an MBA from the Indian Institute of Management.

TalWenderow

Tal Wenderow

DIRECTOR

Mr. Wenderow is a Healthtech executive with a proven track record in bringing innovative & disruptive technologies to the healthcare market.

Mr. Wenderow is currently the President & CEO of Vocalis Health a global technology leader in vocal biomarkers developing voice-enabled AI solutions to create proprietary vocal biomarkers for personalized healthcare screening and continuous remote monitoring of health by using a simple voice sample.

Prior to Vocalis Health Mr. Wenderow co-founded Corindus Vascular Robotics, acquired by Siemens Healthineers in 2019 for ~$1.1B; In his last position he served as the Executive Vice President of International & Business Development responsible for global sales and business partnerships of Corindus.

Mr. Wenderow holds a Bachelor of Science, Summa Cum Laude, in Mechanical Engineering from Technion in Israel and completed the Executive Program for Life Sciences at the Merage Foundation, Merage Business School, University of California, Irvine, CA, and has numerous patents issued based on his inventions.

SCIENTIFIC ADVISORY BOARD

Prof. Moshe Shoham

SCIENTIFIC DIRECTOR

Prof Shoham is also the founder of Mazor Robotics Ltd, (Nasdaq: MZOR), a growing medical device company in the field of surgical robotics, recently sold to Medtronic for $1.6 Billion Prof. Shoham is the inventor of the company’s technologies and is a co-founder of the Company. Prof. Shoham is a worldwide acclaimed authority on the field of robotics and has been conducting research in this field for over 25 years with special focus on kinematics and dynamics of robots, sensor integration and medical applications. Prof Shoham is the head of the robotics lab at the Technion’s faculty of Mechanical Engineering. Prof. Shohan was formerly the director of the robotic laboratory of the Department of Mechanical Engineering at Columbia University in NY. Prof Shoham is also the founder of Mazor Surgical Technologies Ltd, (Nasdaq: MZOR), a growing medical device company in the field of surgical robotics. Prof Shoham has published over 150 conference and journal papers and he is the author of three books.

simon_hi_res

Simon Sharon

CHAIRMANSCIENTIFIC ADVISORY BOARD

Mr. Sharon is a seasoned medical device executive with over 30 years of industry experience. Prior to rejoining Microbot, Simon served as the Chief Technology Officer at MEDX Xelerator, an Israel-based medical device and digital health incubator with partners such as Boston Scientific Corporation and Intellectual Ventures. He was also the Chairman of the Scientific Board at XACT Robotics, a private Israeli company developing a novel platform robotic technology for needle steering in minimally invasive interventional procedures. Prior to this, Mr. Sharon held the position of Chief Operating Officer at Microbot Medical Ltd. before it became a publicly traded company. Prior to joining Microbot in 2013, Mr. Sharon was the Vice President of Research & Development with IceCure Medical, a TASE traded company developing a portfolio of cryogenic ablation systems. Prior to IceCure, he held roles of increasing responsibility at Rockwell Automation–Anorad Israel Ltd, a leading linear motor-based, precision positioning equipment manufacturer. Prior to Rockwell, Simon was the Research & Development Manager at Disc-O-Tech Medical Technologies Ltd., a private orthopedic venture that was acquired by Kyphon (currently part of Medtronic), and before this was the Research & Development Manager at CI Systems, a worldwide supplier of a wide range of electro-optical test and measurement equipment.

eric-leuthardt

Eric C. Leuthardt, MD

SCIENTIFIC DIRECTOR

Eric C. Leuthardt, M.D. is a neurosurgeon who is currently an associate professor with the Department of Neurological Surgery, and the Departments of Neurobiology, Biomedical Engineering, Mechanical Engineering and Material Sciences at Washington University in St. Louis. He is Director of the Center for Innovation in Neuroscience and Technology. He received his B.S. in Biology and Theology at St. Louis University in 1995 and received his M.D. at the University of Pennsylvania’s School of Medicine in 1999. He went on to complete his training at Barnes Jewish Hospital and Washington University in St. Louis in 2005 and then completed a combined fellowship in epilepsy and spinal surgery at the University of Washington in Seattle in 2006. His research has focused on neuroprosthetics – devices linked to the brain that may restore function to patients with motor disabilities. His work in the field of neuroprosthetics and neurosurgical devices has yielded him numerous accolades as a scientist, a neurosurgeon, and an inventor. Dr. Leuthardt uses an integrated approach by employing multiple domains of expertise ranging from biomedical engineering, clinical neurosurgery, mathematical modeling, complex signal analysis, and computer programming. In addition to numerous peer-reviewed publications, Leuthardt has over 1000 patents on file with the U.S. Patent and Trademark Office for medical devices and brain computer interface technologies. He is also the founder of five startup companies.